Citius Oncology, Stock Current Asset
| CTOR Stock | 0.94 0.06 6.00% |
Citius Oncology, fundamentals help investors to digest information that contributes to Citius Oncology,'s financial success or failures. It also enables traders to predict the movement of Citius Stock. The fundamental analysis module provides a way to measure Citius Oncology,'s intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Citius Oncology, stock.
As of 11/28/2024, Non Current Assets Total is likely to drop to about 32 M. In addition to that, Total Current Assets is likely to drop to about 5.7 M. Citius |
Citius Oncology, Company Current Asset Analysis
Citius Oncology,'s Current Asset is all of the company's assets that can be used to pay off current liabilities within the current fiscal period or over the next 12 months. Current Asset includes cash or cash equivalents, accounts receivable, short-term investments, and the portion of prepaid liabilities which will be paid within the next 12 months. Because these assets are easily turned into cash, they are sometimes referred to as liquid assets.
Citius Current Asset Driver Correlations
Understanding the fundamental principles of building solid financial models for Citius Oncology, is extremely important. It helps to project a fair market value of Citius Stock properly, considering its historical fundamentals such as Current Asset. Since Citius Oncology,'s main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Citius Oncology,'s historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Citius Oncology,'s interrelated accounts and indicators.
Click cells to compare fundamentals
Citius Current Asset Historical Pattern
Today, most investors in Citius Oncology, Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Citius Oncology,'s growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current asset growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Citius Oncology, current asset as a starting point in their analysis.
Citius Oncology, Current Asset |
| Timeline |
Current Asset is important to company's creditors and private equity firms as they will often be interested in how much that company has in current assets since these assets can be easily liquidated in case the company goes bankrupt. However, it is usually not enough to know if a company is in good shape just based on current asset alone; the amount of current liabilities should always be considered.
| Competition |
Citius Total Assets
Total Assets |
|
In accordance with the recently published financial statements, Citius Oncology, has a Current Asset of 0.0. This indicator is about the same for the Life Sciences Tools & Services average (which is currently at 0.0) sector and about the same as Health Care (which currently averages 0.0) industry. This indicator is about the same for all United States stocks average (which is currently at 0.0).
Citius Current Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Citius Oncology,'s direct or indirect competition against its Current Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Citius Oncology, could also be used in its relative valuation, which is a method of valuing Citius Oncology, by comparing valuation metrics of similar companies.Citius Oncology, is currently under evaluation in current asset category among its peers.
Citius Fundamentals
| Current Valuation | 116.23 M | ||||
| Shares Outstanding | 2 M | ||||
| Number Of Shares Shorted | 39.42 K | ||||
| Price To Book | 4.55 X | ||||
| Market Capitalization | 116.23 M |
About Citius Oncology, Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Citius Oncology,'s financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Citius Oncology, using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Citius Oncology, based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Citius Oncology,
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Citius Oncology, position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Citius Oncology, will appreciate offsetting losses from the drop in the long position's value.Moving together with Citius Stock
Moving against Citius Stock
| 0.8 | BMY | Bristol Myers Squibb Aggressive Push | PairCorr |
| 0.72 | ESPR | Esperion Therapeutics | PairCorr |
| 0.7 | GILD | Gilead Sciences | PairCorr |
| 0.67 | FLGC | Flora Growth Corp | PairCorr |
| 0.6 | NBY | NovaBay Pharmaceuticals | PairCorr |
The ability to find closely correlated positions to Citius Oncology, could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Citius Oncology, when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Citius Oncology, - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Citius Oncology, to buy it.
The correlation of Citius Oncology, is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Citius Oncology, moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Citius Oncology, moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Citius Oncology, can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Citius Stock Analysis
When running Citius Oncology,'s price analysis, check to measure Citius Oncology,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Citius Oncology, is operating at the current time. Most of Citius Oncology,'s value examination focuses on studying past and present price action to predict the probability of Citius Oncology,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Citius Oncology,'s price. Additionally, you may evaluate how the addition of Citius Oncology, to your portfolios can decrease your overall portfolio volatility.